Ribosomal protein S27-like is a physiological regulator of p53 that suppresses genomic instability and tumorigenesis

eLife

Volumn 3, Issue August2014, 2014, Pages 1-28

  Xiong, Xiufang ^a   Zhao, Yongchao ^a   Tang, Fei ^b   Wei, Dongping ^a   Thomas, Daffyd ^c   Wang, Xiang ^a   Liu, Yang ^b   Zheng, Pan ^b   Sun, Yi ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PROTEIN S27; RIBOSOME PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; MDM2 PROTEIN, MOUSE; MDM4 PROTEIN, MOUSE; ONCOPROTEIN; RPS27L PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANEUPLOIDY; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL TRANSPLANTATION; CONTROLLED STUDY; FLOW CYTOMETRY; GENE DELETION; GENOMIC INSTABILITY; GENOTYPE; HEMATOPOIETIC STEM CELL; HETEROZYGOSITY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; METAPHASE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; UBIQUITINATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL CULTURE; CYTOLOGY; FIBROBLAST; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LYMPHOMA; MAMMALIAN EMBRYO; METABOLISM; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

MUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOGENESIS; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; LYMPHOMA; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, FLUORESCENCE; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBOSOMAL PROTEINS; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84926161397     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.02236     Document Type: Article

References (95)

1. Abbas HA, Maccio DR, Coskun S, Jackson JG, Hazen AL, Sills TM, You MJ, Hirschi KK, Lozano G. 2010. Mdm2 is required for survival of hematopoietic stem cells/progenitors via dampening of ROS-induced p53 activity. Cell Stem Cell 7:606-617. doi: 10.1016/j.stem.2010.09.013.
2. Alt JR, Greiner TC, Cleveland JL, Eischen CM. 2003. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. The EMBO Journal 22:1442-1450. doi: 10.1093/emboj/cdg133.
3. Anderson SJ, Lauritsen JP, Hartman MG, Foushee AM, Lefebvre JM, Shinton SA, Gerhardt B, Hardy RR, Oravecz T, Wiest DL. 2007. Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint. Immunity 26:759-772. doi: 10.1016/j.immuni.2007.04.012.
4. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. 1995. High-frequency developmental abnormalities in p53-deficient mice. Current Biology 5:931-936. doi: 10.1016/S0960-9822(95)00183-7.
5. Barkic M, Crnomarkovic S, Grabusic K, Bogetic I, Panic L, Tamarut S, Cokaric M, Jeric I, Vidak S, Volarevic S. 2009. The p53 tumor suppressor causes congenital malformations in Rpl24-deficient mice and promotes their survival. Molecular and Cellular Biology 29:2489-2504. doi: 10.1128/MCB.01588-08.
6. Barlow JL, Drynan LF, Hewett DR, Holmes LR, Lorenzo-Abalde S, Lane AL, Jolin HE, Pannell R, Middleton AJ, Wong SH, Warren AJ, Wainscoat JS, Boultwood J, McKenzie AN. 2010. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nature Medicine 16:59-66. doi: 10.1038/nm.2063.
7. Bhat KP, Itahana K, Jin A, Zhang Y. 2004. Essential role of ribosomal protein L11 in mediating growth inhibition-induced p53 activation. The EMBO Journal 23:2402-2412. doi: 10.1038/sj.emboj.7600247.
8. Bursac S, Brdovcak MC, Donati G, Volarevic S. 2014. Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochimica et Biophysica Acta 1842:817-830. doi: 10.1016/j.bbadis.2013.08.014.
9. Bursac S, Brdovcak MC, Pfannkuchen M, Orsolic I, Golomb L, Zhu Y, Katz C, Daftuar L, Grabusic K, Vukelic I, Filić V, Oren M, Prives C, Volarevic S. 2012. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proceedings of the National Academy of Sciences of USA 109:20467-20472. doi: 10.1073/pnas.1218535109.
10. Chen C, Liu Y, Zheng P. 2009. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Science Signaling 2:ra75. doi: 10.1126/scisignal.2000559.
11. Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H, Zhang R. 2007. Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene 26:5029-5037. doi: 10.1038/sj.onc.1210327.
12. Cheng Q, Chen L, Li Z, Lane WS, Chen J. 2009. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. The EMBO Journal 28:3857-3867. doi: 10.1038/emboj.2009.294.
13. Cui D, Li L, Lou H, Sun H, Ngai SM, Shao G, Tang J. 2014. The ribosomal protein S26 regulates p53 activity in response to DNA damage. Oncogene 33:2225-2235. doi: 10.1038/onc.2013.170.
14. Daftuar L, Zhu Y, Jacq X, Prives C. 2013. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-Mdmx network. PLOS ONE 8:e68667. doi: 10.1371/journal.pone.0068667.
15. Dai MS, Lu H. 2004. Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. The Journal of Biological Chemistry 279:44475-44482. doi: 10.1074/jbc.M403722200.
16. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. 2004. Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Molecular and Cellular Biology 24:7654-7668. doi: 10.1128/MCB.24.17.7654-7668.2004.
17. de Graaf P, Little NA, Ramos YF, Meulmeester E, Letteboer SJ, Jochemsen AG. 2003. Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2. The Journal of Biological Chemistry 278:38315-38324. doi: 10.1074/jbc.M213034200.
18. de Rozieres S, Maya R, Oren M, Lozano G. 2000. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19:1691-1697. doi: 10.1038/sj.onc.1203468.
19. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. 2000. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. The Journal of Biological Chemistry 275:8945-8951. doi: 10.1074/jbc.275.12.8945.
20. Finch RA, Donoviel DB, Potter D, Shi M, Fan A, Freed DD, Wang CY, Zambrowicz BP, Ramirez-Solis R, Sands AT, Zhang N. 2002. mdmx is a negative regulator of p53 activity in vivo. Cancer Research 62:3221-3225.
21. Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. 2006. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proceedings of the National Academy of Sciences of USA 103:3232-3237. doi: 10.1073/pnas.0508476103.
22. Fumagalli S, Di Cara A, Neb-Gulati A, Natt F, Schwemberger S, Hall J, Babcock GF, Bernardi R, Pandolfi PP, Thomas G. 2009. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nature Cell Biology 11:501-508. doi: 10.1038/ncb1858.
23. Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegue E, Evan GI. 2011. Validation of MdmX as a therapeutic target for reactivating p53 in tumors. Genes & Development 25:1746-1757. doi: 10.1101/gad.16722111.
24. Giaccia AJ, Kastan MB. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes & Development 12:2973-2983. doi: 10.1101/gad.12.19.2973.
25. Gilkes DM, Chen L, Chen J. 2006. MDMX regulation of p53 response to ribosomal stress. The EMBO Journal 25:5614-5625. doi: 10.1038/sj.emboj.7601424.
26. Golomb L, Volarevic S, Oren M. 2014. p53 and ribosome biogenesis stress: The essentials. FEBS Letters 588:2571-2579. doi: 10.1016/j.febslet.2014.04.014.
27. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. 1994. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Research 54:4855-4878.
28. Gu Q, Tan M, Sun Y. 2007. SAG/ROC2/Rbx2 is a novel activator protein-1 target that promotes c-Jun degradation and inhibits 12-O-tetradecanoylphorbol-13-acetate-induced neoplastic transformation. Cancer Research 67:3616-3625. doi: 10.1158/0008-5472.CAN-06-4020.
29. Haupt Y, Maya R, Kazaz A, Oren M. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299. doi: 10.1038/387296a0.
30. He H, Sun Y. 2007. Ribosomal protein S27L is a direct p53 target that regulates apoptosis. Oncogene 26:2707-2716. doi: 10.1038/sj.onc.1210073.
31. Honda R, Tanaka H, Yasuda H. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Letters 420:25-27. doi: 10.1016/S0014-5793(97)01480-4.
32. Honda R, Yasuda H. 2000. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19:1473-1476. doi: 10.1038/sj.onc.1203464.
33. Huang CJ, Yang SH, Lee CL, Cheng YC, Tai SY, Chien CC. 2013. Ribosomal protein S27-like in colorectal cancer: a candidate for predicting prognoses. PLOS ONE 8:e67043. doi: 10.1371/journal.pone.0067043.
34. Huang L, Yan Z, Liao X, Li Y, Yang J, Wang ZG, Zuo Y, Kawai H, Shadfan M, Ganapathy S, Yuan ZM. 2011. The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proceedings of the National Academy of Sciences of USA 108:12001-12006. doi: 10.1073/pnas.1102309108.
35. Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, Zhang Y. 2003. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Molecular Cell 12:1151-1164. doi: 10.1016/S1097-2765(03)00431-3.
36. Itahana K, Mao H, Jin A, Itahana Y, Clegg HV, Lindstrom MS, Bhat KP, Godfrey VL, Evan GI, Zhang Y. 2007. Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell 12:355-366. doi: 10.1016/j.ccr.2007.09.007.
37. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Current Biology 4:1-7. doi: 10.1016/S0960-9822(00)00002-6.
38. Jin A, Itahana K, O'Keefe K, Zhang Y. 2004. Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Molecular and Cellular Biology 24:7669-7680. doi: 10.1128/MCB.24.17.7669-7680.2004.
39. Jones NC, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey JP, Glynn EF, Ellington L, Du C, Dixon J, Dixon MJ, Trainor PA. 2008. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nature Medicine 14:125-133. doi: 10.1038/nm1725.
40. Jones SN, Roe AE, Donehower LA, Bradley A. 1995. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208. doi: 10.1038/378206a0.
41. Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM. 2007. RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Research 67:6026-6030. doi: 10.1158/0008-5472.CAN-07-1313.
42. Kawai H, Wiederschain D, Kitao H, Stuart J, Tsai KK, Yuan ZM. 2003. DNA damage-induced MDMX degradation is mediated by MDM2. The Journal of Biological Chemistry 278:45946-45953. doi: 10.1074/jbc.M308295200.
43. Kibe R, Zhang S, Guo D, Marrero L, Tsien F, Rodriguez P, Khan S, Zieske A, Huang J, Li W, Durum SK, Iwakuma T, Cui Y. 2012. IL-7Ralpha deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell Death and Differentiation 19:1139-1151. doi: 10.1038/cdd.2011.203.
44. Ko LJ, Prives C. 1996. p53: puzzle and paradigm. Genes & Development 10:1054-1072. doi: 10.1101/gad.10.9.1054.
45. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE. 2006. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. Journal of Molecular Biology 363:433-450. doi: 10.1016/j.jmb.2006.08.027.
46. Kruse JP, Gu W. 2009. Modes of p53 regulation. Cell 137:609-622. doi: 10.1016/j.cell.2009.04.050.
47. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303. doi: 10.1038/387299a0.
48. Levine AJ. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331. doi: 10.1016/S0092-8674(00)81871-1.
49. Levine AJ, Oren M. 2009. The first 30 years of p53: growing ever more complex. Nature Reviews Cancer 9:749-758. doi: 10.1038/nrc2723.
50. Li J, Tan J, Zhuang L, Banerjee B, Yang X, Chau JF, Lee PL, Hande MP, Li B, Yu Q. 2007. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Research 67:11317-11326. doi: 10.1158/0008-5472.CAN-07-1088.
51. Linares LK, Hengstermann A, Ciechanover A, Muller S, Scheffner M. 2003. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53. Proceedings of the National Academy of Sciences of USA 100:12009-12014. doi: 10.1073/pnas.2030930100.
52. Lindstrom MS, Zhang Y. 2008. Ribosomal protein S9 is a novel B23/NPM-binding protein required for normal cell proliferation. The Journal of Biological Chemistry 283:15568-15576. doi: 10.1074/jbc.M801151200.
53. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, Vousden KH. 2003. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3:577-587. doi: 10.1016/S1535-6108(03)00134-X.
54. Macias E, Jin A, Deisenroth C, Bhat K, Mao H, Lindstrom MS, Zhang Y. 2010. An ARF-independent c-MYC-activated tumor suppression pathway mediated by ribosomal protein-Mdm2 Interaction. Cancer Cell 18:231-243. doi: 10.1016/j.ccr.2010.08.007.
55. McGowan KA, Li JZ, Park CY, Beaudry V, Tabor HK, Sabnis AJ, Zhang W, Fuchs H, de Angelis MH, Myers RM, Attardi LD, Barsh GS. 2008. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nature Genetics 40:963-970. doi: 10.1038/ng.188.
56. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman RN, Powell DA, Perry ME. 2006. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes & Development 20:16-21. doi: 10.1101/gad.1378506.
57. Migliorini D, Lazzerini Denchi E, Danovi D, Jochemsen A, Capillo M, Gobbi A, Helin K, Pelicci PG, Marine JC. 2002. Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development. Molecular and Cellular Biology 22:5527-5538. doi: 10.1128/MCB.22.15.5527-5538.2002.
58. Montes de Oca Luna R, Wagner DS, Lozano G. 1995. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206. doi: 10.1038/378203a0.
59. Ofir-Rosenfeld Y, Boggs K, Michael D, Kastan MB, Oren M. 2008. Mdm2 regulates p53 mRNA translation through inhibitory interactions with ribosomal protein L26. Molecular Cell 32:180-189. doi: 10.1016/j.molcel.2008.08.031.
60. Pan Y, Chen J. 2003. MDM2 promotes ubiquitination and degradation of MDMX. Molecular and Cellular Biology 23:5113-5121. doi: 10.1128/MCB.23.15.5113-5121.2003.
61. Panic L, Tamarut S, Sticker-Jantscheff M, Barkic M, Solter D, Uzelac M, Grabusic K, Volarevic S. 2006. Ribosomal protein S6 gene haploinsufficiency is associated with activation of a p53-dependent checkpoint during gastrulation. Molecular and Cellular Biology 26:8880-8891. doi: 10.1128/MCB.00751-06.
62. Pant V, Xiong S, Iwakuma T, Quintas-Cardama A, Lozano G. 2011. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability. Proceedings of the National Academy of Sciences of USA 108:11995-12000. doi: 10.1073/pnas.1102241108.
63. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, Lozano G. 2001. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nature Genetics 29:92-95. doi: 10.1038/ng714.
64. Poortinga G, Hannan KM, Snelling H, Walkley CR, Jenkins A, Sharkey K, Wall M, Brandenburger Y, Palatsides M, Pearson RB, McArthur GA, Hannan RD. 2004. MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. The EMBO Journal 23:3325-3335. doi: 10.1038/sj.emboj.7600335.
65. Poyurovsky MV, Priest C, Kentsis A, Borden KL, Pan ZQ, Pavletich N, Prives C. 2007. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity. The EMBO Journal 26:90-101. doi: 10.1038/sj.emboj.7601465.
66. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. 1995. A subset of p53-deficient embryos exhibit exencephaly. Nature Genetics 10:175-180. doi: 10.1038/ng0695-175.
67. Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, Itoh B, Wang J, Komatsu Y, Yang YR, Hikasa H, Horie Y, Yamashita T, Kamijo T, Zhang Y, Zhu Y, Prives C, Nakano T, Mak TW, Sasaki T, Maehama T, Mori M, Suzuki A. 2011. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nature Medicine 17:944-951. doi: 10.1038/nm.2392.
68. Sharp DA, Kratowicz SA, Sank MJ, George DL. 1999. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. The Journal of Biological Chemistry 274:38189-38196. doi: 10.1074/jbc.274.53.38189.
69. Shvarts A, Steegenga WT, Riteco N, van Laar T, Dekker P, Bazuine M, van Ham RC, van der Houven van Oordt W, Hateboer G, van der Eb AJ, Jochemsen AG. 1996. MDMX: a novel p53-binding protein with some functional properties of MDM2. The EMBO Journal 15:5349-5357.
70. Sulic S, Panic L, Barkic M, Mercep M, Uzelac M, Volarevic S. 2005. Inactivation of S6 ribosomal protein gene in T lymphocytes activates a p53-dependent checkpoint response. Genes & Development 19:3070-3082. doi: 10.1101/gad.359305.
71. Sun XX, DeVine T, Challagundla KB, Dai MS. 2011. Interplay between ribosomal protein S27a and MDM2 protein in p53 activation in response to ribosomal stress. The Journal of Biological Chemistry 286:22730-22741. doi: 10.1074/jbc.M111.223651.
72. Tan M, Davis SW, Saunders TL, Zhu Y, Sun Y. 2009. RBX1/ROC1 disruption results in early embryonic lethality due to proliferation failure, partially rescued by simultaneous loss of p27. Proceedings of the National Academy of Sciences of USA 106:6203-6208. doi: 10.1073/pnas.0812425106.
73. Tang F, Wu Q, Ikenoue T, Guan KL, Liu Y, Zheng P. 2012. A critical role for Rictor in T lymphopoiesis. The Journal of Immunology 189:1850-1857. doi: 10.4049/jimmunol.1201057.
74. Tanimura S, Ohtsuka S, Mitsui K, Shirouzu K, Yoshimura A, Ohtsubo M. 1999. MDM2 interacts with MDMX through their RING finger domains. FEBS Letters 447:5-9. doi: 10.1016/S0014-5793(99)00254-9.
75. Terzian T, Dumble M, Arbab F, Thaller C, Donehower LA, Lozano G, Justice MJ, Roop DR, Box NF. 2011. Rpl27a mutation in the sooty foot ataxia mouse phenocopies high p53 mouse models. The Journal of Pathology 224:540-552. doi: 10.1002/path.2891.
76. Terzian T, Wang Y, Van Pelt CS, Box NF, Travis EL, Lozano G. 2007. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Molecular and Cellular Biology 27:5479-5485. doi: 10.1128/MCB.00555-06.
77. Uldrijan S, Pannekoek WJ, Vousden KH. 2007. An essential function of the extreme C-terminus of MDM2 can be provided by MDMX. The EMBO Journal 26:102-112. doi: 10.1038/sj.emboj.7601469.
78. Vogelstein B, Lane D, Levine AJ. 2000. Surfing the p53 network. Nature 408:307-310. doi: 10.1038/35042675.
79. Volarevic S, Stewart MJ, Ledermann B, Zilberman F, Terracciano L, Montini E, Grompe M, Kozma SC, Thomas G. 2000. Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. Science 288:2045-2047. doi: 10.1126/science.288.5473.2045.
80. Wade M, Li YC, Wahl GM. 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nature Reviews Cancer 13:83-96. doi: 10.1038/nrc3430.
81. Wang X, Wang J, Jiang X. 2011. MdmX protein is essential for Mdm2 protein-mediated p53 polyubiquitination. The Journal of Biological Chemistry 286:23725-23734. doi: 10.1074/jbc.M110.213868.
82. Wang Y, Yang J, Zheng H, Tomasek GJ, Zhang P, McKeever PE, Lee EY, Zhu Y. 2009a. Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. Cancer Cell 15:514-526. doi: 10.1016/j.ccr.2009.04.001.
83. Wang Z, Zheng M, Li Z, Li R, Jia L, Xiong X, Southall N, Wang S, Xia M, Austin CP, Zheng W, Xie Z, Sun Y. 2009b. Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Research 69:6556-6564. doi: 10.1158/0008-5472.CAN-09-0891.
84. Wu J, Chen Y, Lu LY, Wu Y, Paulsen MT, Ljungman M, Ferguson DO, Yu X. 2011. Chfr and RNF8 synergistically regulate ATM activation. Nature Structural & Molecular Biology 18:761-768. doi: 10.1038/nsmb.2078.
85. Wu X, Bayle JH, Olson D, Levine AJ. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes & Development 7:1126-1132. doi: 10.1101/gad.7.7a.1126.
86. Xiong X, Zhao Y, He H, Sun Y. 2011. Ribosomal protein S27-like and S27 interplay with p53-MDM2 axis as a target, a substrate and a regulator. Oncogene 30:1798-1811. doi: 10.1038/onc.2010.569.
87. Yadavilli S, Mayo LD, Higgins M, Lain S, Hegde V, Deutsch WA. 2009. Ribosomal protein S3: a multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair 8:1215-1224. doi: 10.1016/j.dnarep.2009.07.003.
88. Zhang X, Wang W, Wang H, Wang MH, Xu W, Zhang R. 2013. Identification of ribosomal protein S25 (RPS25)-MDM2-p53 regulatory feedback loop. Oncogene 32:2782-2791. doi: 10.1038/onc.2012.289.
89. Zhang Y, Lu H. 2009. Signaling to p53: ribosomal proteins find their way. Cancer Cell 16:369-377. doi: 10.1016/j.ccr.2009.09.024.
90. Zhang Y, Wang J, Yuan Y, Zhang W, Guan W, Wu Z, Jin C, Chen H, Zhang L, Yang X, He F. 2010. Negative regulation of HDM2 to attenuate p53 degradation by ribosomal protein L26. Nucleic Acids Research 38:6544-6554. doi: 10.1093/nar/gkq536.
91. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, Xiong Y. 2003. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Molecular and Cellular Biology 23:8902-8912. doi: 10.1128/MCB.23.23.8902-8912.2003.
92. Zhou X, Hao Q, Liao J, Zhang Q, Lu H. 2013. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 32:388-396. doi: 10.1038/onc.2012.63.
93. Zhou X, Liao JM, Liao WJ, Lu H. 2012. Scission of the p53-MDM2 Loop by Ribosomal Proteins. Genes Cancer 3:298-310. doi: 10.1177/1947601912455200.
94. Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X, Prives C. 2009. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Molecular Cell 35:316-326. doi: 10.1016/j.molcel.2009.07.014.
95. Zhu Y, Wang X, Goff SP, Gao G. 2012. Translational repression precedes and is required for ZAP-mediated mRNA decay. The EMBO Journal 31:4236-4246. doi: 10.1038/emboj.2012.271.